CA2982704C - Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection - Google Patents
Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection Download PDFInfo
- Publication number
- CA2982704C CA2982704C CA2982704A CA2982704A CA2982704C CA 2982704 C CA2982704 C CA 2982704C CA 2982704 A CA2982704 A CA 2982704A CA 2982704 A CA2982704 A CA 2982704A CA 2982704 C CA2982704 C CA 2982704C
- Authority
- CA
- Canada
- Prior art keywords
- purin
- compound
- amino
- methyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/078507 | 2015-05-08 | ||
| CN2015078507 | 2015-05-08 | ||
| CNPCT/CN2016/078785 | 2016-04-08 | ||
| CN2016078785 | 2016-04-08 | ||
| PCT/EP2016/059961 WO2016180695A1 (en) | 2015-05-08 | 2016-05-04 | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2982704A1 CA2982704A1 (en) | 2016-11-17 |
| CA2982704C true CA2982704C (en) | 2023-10-24 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2982704A Active CA2982704C (en) | 2015-05-08 | 2016-05-04 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9708325B2 (https=) |
| EP (1) | EP3294740B1 (https=) |
| JP (1) | JP6738352B2 (https=) |
| KR (1) | KR102690131B1 (https=) |
| CN (1) | CN107580596B (https=) |
| AR (1) | AR104528A1 (https=) |
| AU (3) | AU2016260683B2 (https=) |
| BR (1) | BR112017023959B1 (https=) |
| CA (1) | CA2982704C (https=) |
| CL (1) | CL2017002745A1 (https=) |
| CO (1) | CO2017009994A2 (https=) |
| CR (1) | CR20170496A (https=) |
| DK (1) | DK3294740T3 (https=) |
| ES (1) | ES2753777T3 (https=) |
| HR (1) | HRP20191942T1 (https=) |
| HU (1) | HUE045906T2 (https=) |
| IL (2) | IL254947B (https=) |
| LT (1) | LT3294740T (https=) |
| MX (2) | MX393198B (https=) |
| MY (1) | MY182353A (https=) |
| NZ (2) | NZ775222A (https=) |
| PE (1) | PE20171620A1 (https=) |
| PH (1) | PH12017502009A1 (https=) |
| PL (1) | PL3294740T3 (https=) |
| PT (1) | PT3294740T (https=) |
| RS (1) | RS59435B1 (https=) |
| RU (1) | RU2745269C2 (https=) |
| SG (1) | SG10202108841YA (https=) |
| SI (1) | SI3294740T1 (https=) |
| TW (2) | TWI706954B (https=) |
| UA (1) | UA120450C2 (https=) |
| WO (1) | WO2016180695A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3294740T3 (pl) | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| PL3504210T3 (pl) * | 2016-08-29 | 2021-07-05 | F. Hoffmann-La Roche Ag | 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych |
| EP3512556B1 (en) | 2016-09-13 | 2021-08-18 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| JP7089596B2 (ja) * | 2018-02-28 | 2022-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| CA3128081A1 (en) * | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| US12503461B2 (en) | 2019-09-20 | 2025-12-23 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents |
| WO2021154662A1 (en) * | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097105A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| EP4554678A1 (en) | 2022-07-14 | 2025-05-21 | F. Hoffmann-La Roche AG | Phosphorylpurinone compounds for the treatment of cancer |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| AU2006242920A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| RS53347B (sr) * | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TWI555737B (zh) * | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| JP6349256B2 (ja) | 2011-11-09 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのプリン誘導体 |
| CN110590809B (zh) | 2013-03-29 | 2022-04-19 | 爱尔兰詹森科学公司 | 用于治疗病毒感染的大环脱氮-嘌呤酮 |
| HRP20210927T1 (hr) | 2014-08-15 | 2021-09-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Spojevi pirolopirimidina koje se koriste kao agonist tlr7 |
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| PL3504210T3 (pl) * | 2016-08-29 | 2021-07-05 | F. Hoffmann-La Roche Ag | 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych |
-
2016
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt not_active IP Right Cessation
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh not_active IP Right Cessation
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2982704C (en) | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| EP3458455B1 (en) | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases | |
| JP6936848B2 (ja) | 感染症の治療のための新規テトラヒドロピラゾロピリジン化合物 | |
| ES2652648T3 (es) | Moduladores P2X7 | |
| TW201834657A (zh) | 聚－adp核糖聚合酶（parp）抑制劑 | |
| CN111868051A (zh) | 作为ctps1抑制剂的氨基嘧啶衍生物 | |
| JP2018527309A (ja) | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン | |
| BR112016023554B1 (pt) | Novos compostos macrocíclicos | |
| JP2018532735A (ja) | 新規な修飾された大環状化合物 | |
| CA3057891A1 (en) | Novel ptefb inhibiting macrocyclic compounds | |
| AU2022451580B2 (en) | Parp7 inhibitor and use thereof | |
| JP2017511325A (ja) | スルホンジイミン基を含むジ置換５−フルオロピリミジン誘導体 | |
| CA3180661A1 (en) | Cycloalkyl pyrimidines as ferroportin inhibitors | |
| HK1247925B (zh) | 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251202 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260316 |